252P - Hypofractionated intensity modulated radiotherapy in intermediate and high risk groups for localised prostate cancer: experience from an Indian ter...

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Prostate Cancer
Surgical Oncology
Radiation Oncology
Presenter Sanjay Hunugundmath
Citation Annals of Oncology (2015) 26 (suppl_9): 71-79. 10.1093/annonc/mdv524
Authors S.M. Hunugundmath1, B. Kunheri2
  • 1Radiation Oncology, amrita institute of medical sciences, 682041 - Cochin/IN
  • 2Radiation Oncology, amrita institute of medical sciences, Cochin/IN



AIM To study the predictive factors of survival and outcomes in patients treated for localised prostate cancer with 70Gy delivered at 2.5Gy per fraction.


A total of 120 biopsy proven localised prostate cancer patients were treated with hypofractionated Intensity Modulated radiotherapy from 2007-2011.Patients were treated with radiation to prostate and pelvic nodes and hormone for 6m to 2 years depending on the risk group. The total dose delivered using SIB-IMRT was 70Gy in 28 fractions at 2.5Gy per fraction to prostate and 50.4Gy in 28 fractions to whole pelvis.The survival analysis was done using Kaplan meier survival curves, and univariate analysis was done using log rank test.


The median follow up of our patients was 24 months (range 1-72months).The DFS at 12months, 24months and 36months were 97%, 94% and 88% respectively. The number of patients with biochemical recurrence alone were 2(2%). We found that Gleasons score and post neo adjuvant PSA before the start of radiotherapy were statistically significant prognostic variable in terms of disease free survival with a pvalue of (0.000) and (0.05) respectively.All our patients had grade 1 or 2 rectal and bladder acute toxicities.50 out of 121(42%) had late grade 1 rectal and bladder toxicities,grade 2 toxicities were found in 15 patients (12%).Late grade 3 rectal toxicities was seen only in 1 patient.


Post neoadjuvant serum PSA levels and Gleasons score, co related well with DFS in our patients and hypofractionated SIB- IMRT was tolerated well with minimal toxicities.

Clinical trial identification


All authors have declared no conflicts of interest.